Translate Bio
Translate Bio is a clinical-stage mRNA therapeutics company developing medicines to treat diseases caused by protein or gene dysfunction and vaccines against infectious disease pathogens.
6
Funding Rounds
$227.7m
Money raised
Overview
Translate Bio is a clinical-stage mRNA therapeutics company developing medicines to treat diseases caused by protein or gene dysfunction and vaccines against infectious disease pathogens.
-
Website:
- Business model: B2B
- Social accounts:
Funding
Funding series
Funding Series Analysis
The company Translate Bio has raised a total of $227.66m in funding over 6 rounds.
Key Insights:
- Translate Bio Venture round, May 3, 2019: $47.5m
- Translate Bio Series C round, December 1, 2017: $42m
- Translate Bio Series C round, January 10, 2017: $51m
- Translate Bio Series B round, July 30, 2015: $63.8m
- Translate Bio Series A round: $20.7m
- Translate Bio funding round, November 2011: $2.66m
Translate Bio Venture round, May 3, 2019
$47.5m
Translate Bio Series C round, December 1, 2017
$42m
Translate Bio Series C round, January 10, 2017
$51m
Translate Bio Series B round, July 30, 2015
$63.8m
Translate Bio Series A round
$20.7m
Translate Bio funding round, November 2011
$2.66m
Industries
Translate Bio is active in the following industries: